Ensign Peak Advisors Inc Raises Stock Holdings in RxSight, Inc. (NASDAQ:RXST)

Ensign Peak Advisors Inc lifted its position in RxSight, Inc. (NASDAQ:RXST - Free Report) by 26.6% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 132,884 shares of the company's stock after purchasing an additional 27,913 shares during the period. Ensign Peak Advisors Inc owned about 0.33% of RxSight worth $4,569,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in RXST. Private Trust Co. NA bought a new stake in RxSight during the 4th quarter valued at approximately $34,000. Coppell Advisory Solutions LLC boosted its position in shares of RxSight by 108.9% during the fourth quarter. Coppell Advisory Solutions LLC now owns 1,289 shares of the company's stock valued at $44,000 after purchasing an additional 672 shares in the last quarter. Arcadia Investment Management Corp MI purchased a new stake in RxSight in the fourth quarter worth $46,000. Harbor Investment Advisory LLC purchased a new position in RxSight during the 4th quarter valued at about $52,000. Finally, Global Retirement Partners LLC bought a new position in shares of RxSight during the fourth quarter valued at approximately $69,000. 78.78% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on RXST. UBS Group lowered RxSight from a "buy" rating to a "neutral" rating and lowered their price target for the stock from $45.00 to $16.00 in a research report on Wednesday, April 9th. Wells Fargo & Company upgraded shares of RxSight from an "equal weight" rating to an "overweight" rating and upped their target price for the stock from $17.00 to $25.00 in a research note on Monday. Bank of America reissued an "underperform" rating and set a $22.00 price target (down previously from $36.00) on shares of RxSight in a research report on Thursday, April 3rd. Stifel Nicolaus decreased their price objective on shares of RxSight from $33.00 to $28.00 and set a "hold" rating for the company in a report on Wednesday, March 19th. Finally, JPMorgan Chase & Co. reaffirmed an "underweight" rating and set a $17.00 price objective (down from $40.00) on shares of RxSight in a research report on Friday, April 4th. Two analysts have rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, RxSight presently has a consensus rating of "Hold" and an average price target of $37.90.

Insider Activity

In other news, Director Tamara Fountain sold 7,000 shares of the stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $25.71, for a total transaction of $179,970.00. Following the completion of the transaction, the director now directly owns 24,793 shares in the company, valued at approximately $637,428.03. This represents a 22.02% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 9.36% of the company's stock.

RxSight Price Performance

Shares of RXST traded down $0.09 on Tuesday, reaching $16.23. The company's stock had a trading volume of 196,452 shares, compared to its average volume of 676,676. The stock's 50 day simple moving average is $17.89 and its two-hundred day simple moving average is $29.71. The stock has a market capitalization of $659.54 million, a P/E ratio of -19.55 and a beta of 1.32. RxSight, Inc. has a 12-month low of $12.53 and a 12-month high of $64.50.

RxSight (NASDAQ:RXST - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported ($0.03) earnings per share for the quarter, meeting the consensus estimate of ($0.03). RxSight had a negative return on equity of 14.00% and a negative net margin of 23.92%. The company had revenue of $37.90 million for the quarter, compared to the consensus estimate of $38.74 million. During the same period in the previous year, the business earned ($0.25) earnings per share. RxSight's quarterly revenue was up 28.5% compared to the same quarter last year. Analysts expect that RxSight, Inc. will post -0.7 earnings per share for the current year.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.